Risk Stratification for Acute Kidney Injury: Are Biomarkers Enough?

Blaithin A. McMahon, Jay L. Koyner

Research output: Contribution to journalReview articlepeer-review

Abstract

Acute kidney injury (AKI) is a common and serious complication that is associated with several adverse outcomes in hospitalized patients. AKI significantly increases the risk of mortality, need for renal replacement therapy, and intensive care admission, and it also has serious economic ramifications. Effective risk stratification to identify patients at risk for severe AKI is essential for targeting our health care and research resources to tackle this important public health issue. The overwhelming majority of research in earlier diagnosis and risk stratification of AKI over the past 10 years has focused on novel biomarker development. The purpose of this review is to provide an update on other novel risk stratification tools than can be used in the prognostication of AKI. We discuss the utility of the furosemide stress test in predicting the severity of AKI and the renal angina index in predicting the occurrence of AKI. We also discuss NephroCheck, a prognostic test that measures tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 for the early detection of severe AKI.

Original languageEnglish (US)
Pages (from-to)167-178
Number of pages12
JournalAdvances in Chronic Kidney Disease
Volume23
Issue number3
DOIs
StatePublished - May 1 2016

Keywords

  • Acute kidney injury
  • Biomarkers
  • Renal replacement therapy
  • Risk assessment

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Risk Stratification for Acute Kidney Injury: Are Biomarkers Enough?'. Together they form a unique fingerprint.

Cite this